Fig. 6

Analysis of the role of anti-EDIII antibodies in virus neutralization: DENV-1 E VLP antiserum was used without prior depletion (a) or treated as follows. It was incubated with immobilized MBP (b) or immobilized MBP-EDIII-1 (c) matrix. Residual antibody titers in these three DENV-1 E VLP antiserum treatment groups (a, b and c), were analyzed in indirect ELISA using purified recombinant MBP-EDIII-1, −2, −3, −4 protein (panel a) or DENV-1, −2, −3 E VLPs (panel b). Residual neutralizing antibody titers (FNT50) in the same three sera groups were estimated using the FACS assay (Panel c)